Regeneron Eylea generics approved by FDA

seekingalpha05-21

The U.S. FDA has approved two biosimilars for Regeneron Pharmaceuticals' (NASDAQ:REGN) blockbuster eye drug Eylea (aflibercept). Opufiz (aflibercept-yszy) from Samsung Biopesis and Yesafili (...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2437510051?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468183222/image_1468183222.jpg","is_english":true,"pubTime":"2024-05-21 00:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2437510051","market":"us","top_or_hot":-1,"title":"Regeneron Eylea generics approved by FDA","media":"seekingalpha","content":"<div>\n<p>The U.S. FDA has approved two biosimilars for Regeneron Pharmaceuticals' (NASDAQ:REGN) blockbuster eye drug Eylea (aflibercept).  Opufiz (aflibercept-yszy) from Samsung Biopesis and Yesafili (...</p>\n\n<a href=\"https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Eylea generics approved by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Eylea generics approved by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 00:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. FDA has approved two biosimilars for Regeneron Pharmaceuticals' (NASDAQ:REGN) blockbuster eye drug Eylea (aflibercept).  Opufiz (aflibercept-yszy) from Samsung Biopesis and Yesafili (...</p>\n\n<a href=\"https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1917777945.USD","symbol_name":"安联专题基金Cl AT Acc","start_time":0,"source_url":"https://seekingalpha.com/news/4108410-regeneron-eylea-generics-approved-by-fda","article_id":"2437510051","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468183222/image_1468183222.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437510051","pubTimestamp":1716221810,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The U.S. FDA has approved two biosimilars for Regeneron Pharmaceuticals'  blockbuster eye drug Eylea .  Opufiz  from Samsung Biopesis and Yesafili  from Biocon were given the agency nod. However, when either product will actually launch is up in the air. A federal court judge in West Virginia on May 17 issued a temporary restraining order of 14 days blocking the launch of Eylea generics.  Given the expiration of key patents on Eylea, Regeneron developed and won approval of a high-dose version of Eylea in August 2023 that can be taken as infrequently as every 16 weeks after initial dosing. In 2023, Regeneron  reported ~$9.2B in Eylea  revenue.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1917777945.USD":"安联专题基金Cl AT Acc","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","REGN":"再生元制药公司","BK4585":"ETF&股票定投概念","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0882574055.USD":"富达全球健康医疗A ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4139":"生物科技","LU0058720904.USD":"联博国际健康护理基金A","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD"},"translate_title":"Regeneron Eylea仿制药获FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"The U.S. FDA has approved two biosimilars for Regeneron Pharmaceuticals' (NASDAQ:REGN) blockbuster eye drug Eylea (aflibercept).  Opufiz (aflibercept-yszy) from Samsung Biopesis and Yesafili (aflibercept-jbvf) from Biocon were given the agency nod. However, when either product will actually launch is up in the air. A federal court judge in West Virginia on May 17 issued a temporary restraining order of 14 days blocking the launch of Eylea generics.  Given the expiration of key patents on Eylea, Regeneron developed and won approval of a high-dose version of Eylea in August 2023 that can be taken as infrequently as every 16 weeks after initial dosing. In 2023, Regeneron (REGN) reported ~$9.2B in Eylea (excluding high-dose version) revenue.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437510051"}